Swedish private equity firm EQT AB is considering selling its controlling stake in Indira IVF Hospital, India’s largest fertility services chain, in a potential transaction that could value the company at at least $1.5 billion. EQT has reportedly started sounding out early interest from prospective buyers and is working with an adviser on the possible sale, according to a Bloomberg report published on November 18, 2026.

The potential exit comes three years after EQT acquired a majority stake in Indira IVF from TA Associates and the company’s founders in 2023. The move could mark a major private equity transaction in India’s healthcare sector, as investors look to monetise their investments in organised fertility services. However, discussions remain preliminary: EQT is still weighing its options and could decide not to proceed with a sale.

Key takeaways

  • EQT is considering a sale of its controlling stake in Indira IVF.
  • The Swedish investment firm could seek a valuation of at least $1.5 billion, according to people familiar with the matter cited by Bloomberg.
  • EQT has reportedly appointed an adviser and sounded out early interest from potential buyers.
  • EQT acquired a majority stake in Indira IVF in 2023 from TA Associates and the company’s founders.
  • Indira IVF operates more than 200 centres across India, according to its website cited in the latest report.
  • The company previously explored an IPO, but its draft prospectus was subsequently withdrawn.
  • A sale would offer EQT an alternative exit route and could attract other private equity funds, healthcare investors and strategic buyers.
  • The discussions are preliminary, and no final sale decision has been made.

EQT considers exit from India’s largest IVF chain

EQT is evaluating a potential sale of Indira IVF as it considers options for its investment in the Indian fertility services provider.

According to Bloomberg, the private equity firm is working with an adviser and has approached prospective buyers to gauge early interest. People familiar with the discussions said EQT may seek a valuation of at least $1.5 billion.

The process is not yet a confirmed auction or completed transaction. EQT is still evaluating its options and could decide against selling the business.

The firm declined to comment on the reported sale discussions.

Indira IVF has become a significant player in India’s organised fertility treatment market, operating a nationwide network of clinics that provide services including in-vitro fertilisation, reproductive medicine, fertility consultations and related treatments.

The company’s scale and established brand could make it attractive to investors looking for exposure to India’s private healthcare sector.

A potential transaction would also give EQT an opportunity to realise value from an investment it made in 2023, when it acquired control of the business.

How EQT acquired control of Indira IVF in 2023

EQT entered Indira IVF through its BPEA Private Equity Fund VIII in July 2023.

The Swedish investment firm agreed to acquire a controlling stake from US-based private equity investor TA Associates and the company’s founding Murdia family.

The founders, including Dr Ajay Murdia, Dr Kshitiz Murdia and Dr Nitiz Murdia, retained a significant minority stake and continued to lead the business.

Indira IVF was founded by Dr Ajay Murdia in Udaipur in 1988. It expanded from a single fertility clinic into a nationwide network and became one of India’s largest assisted reproductive technology providers.

At the time of the 2023 investment, EQT said the company operated 116 centres across 20 states and completed approximately 40,000 IVF cycles annually.

The investment thesis focused on expanding the clinic network, strengthening research and development, improving technology and increasing access to fertility treatment.

EQT also highlighted the relatively low penetration of IVF services in India compared with more developed healthcare markets.

The private equity firm saw an opportunity to build a larger organised fertility platform by investing in technology, clinical capabilities and geographic expansion.

Why the $1.5 billion valuation matters

The reported valuation of at least $1.5 billion places Indira IVF among the major potential private equity transactions in India’s healthcare services market.

A valuation of this size reflects investor interest in healthcare businesses that combine recurring demand, established brands, specialised services and opportunities for expansion.

However, the reported figure should be treated as a potential asking valuation rather than a confirmed market value.

The final price of a transaction would depend on several factors:

  • The company’s revenue and profitability.
  • Growth in the number of IVF cycles and patient volumes.
  • Operating margins across its clinic network.
  • The quality of its clinical outcomes and reputation.
  • Expansion opportunities in existing and new markets.
  • Debt levels, cash generation and capital requirements.
  • The level of interest from competing buyers.

Private equity investors generally assess healthcare service providers using a combination of earnings, cash flow, growth potential and comparable transaction valuations.

A buyer would also need to examine the company’s clinic-level economics, doctor recruitment, laboratory quality, regulatory compliance and patient acquisition costs.

These factors could influence whether prospective investors are willing to meet the valuation EQT is reportedly considering.

Indira IVF’s 200-plus centre network gives it national scale

Indira IVF’s nationwide presence is one of its most important business assets.

The company operates more than 200 centres across India, according to its website cited in the latest reporting.

Its services include:

  • In-vitro fertilisation (IVF)
  • Fertility consultations
  • Embryology and laboratory services
  • Assisted reproductive technology procedures
  • Embryo transfer
  • Other reproductive health services

A nationwide network allows the company to reach patients in multiple cities rather than depending on a limited number of large metropolitan hospitals.

It can also help create operating efficiencies through centralised technology, standardised clinical processes, brand recognition and shared administrative infrastructure.

However, operating a large fertility network is more complicated than expanding a conventional retail or service chain.

Fertility treatment depends heavily on medical expertise, laboratory quality, clinical protocols and patient confidence.

The availability of experienced fertility specialists and embryologists is therefore important to maintaining service quality as the business expands.

The company must also maintain consistent clinical standards across locations while adapting to differences in local demand and healthcare infrastructure.

Why India’s IVF market is attracting private equity investors

India’s fertility treatment market has attracted increasing interest from private equity funds and healthcare investors.

Several structural factors are contributing to the opportunity.

1. Low IVF penetration creates room for expansion

EQT has previously highlighted that IVF treatment penetration in India remains significantly lower than in developed markets.

In its 2023 investment announcement, the firm estimated that India completed around 300,000 IVF cycles annually at the time and expected the market to grow at approximately 15% annually over the following decade.

Its portfolio information also compares India’s IVF penetration with substantially higher levels in the United States and Europe.

These figures are historical estimates from EQT’s investment thesis, not a current measurement of the market.

The underlying opportunity is that a relatively small proportion of India’s population currently accesses assisted reproductive technology services compared with more developed healthcare markets.

Greater awareness, changing family planning patterns, improvements in medical technology and expanding access to specialised clinics could support market growth.

2. Rising awareness of fertility treatment

Fertility treatment is becoming more visible in India’s healthcare conversation.

Couples are increasingly seeking medical advice and specialised treatment for infertility, while improvements in reproductive medicine are expanding the range of available options.

Fertility clinics offer consultations, diagnostic services, IVF procedures and related treatments within specialised healthcare settings.

The growing awareness of these services can increase demand for organised providers with established brands and medical infrastructure.

3. Organised healthcare chains can consolidate the market

India’s fertility sector includes independent clinics, specialist hospitals and organised national chains.

Private equity investors often see opportunities to consolidate fragmented healthcare markets by acquiring smaller providers and integrating them into larger networks.

A larger platform can potentially improve procurement, technology investment, administrative efficiency and access to specialist talent.

Indira IVF has already expanded through acquisitions and geographic expansion, strengthening its position in the sector.

For a prospective buyer, the ability to continue consolidating the market could be an important part of the investment case.

EQT had previously explored an IPO for Indira IVF

A potential sale is not the first exit route considered for Indira IVF.

EQT had previously explored taking the company public through an initial public offering.

According to Bloomberg’s earlier reporting, the firm was considering a Mumbai listing that could raise approximately $400 million and value the company at around $2.5 billion.

That proposal was preliminary, and the valuation and timing were subject to change.

Indira IVF subsequently submitted a draft IPO prospectus in 2025, but the filing was later withdrawn.

The reported sale discussions suggest EQT may now be evaluating a private transaction as another way to exit or reduce its investment.

An IPO and a private sale offer different advantages.

FactorIPOPrivate sale
Buyer or investor basePublic-market investorsPrivate equity funds and strategic buyers
Transaction structureShares offered to public investorsStake transferred to one or more buyers
Valuation processDetermined through investor demand and market conditionsNegotiated between seller and prospective buyers
ExecutionRequires regulatory filings and listing preparationDepends on buyer interest and due diligence
Exit flexibilityCan allow partial or phased shareholder exitsCan provide a negotiated stake sale

An IPO could allow EQT and other shareholders to sell shares over time, subject to applicable rules and market conditions.

A private sale could provide a more direct exit if a buyer is willing to acquire a substantial stake at an acceptable valuation.

The latest reported discussions do not establish that EQT has abandoned the possibility of a public listing permanently.

Who could be interested in buying Indira IVF?

If EQT moves ahead with a sale process, the business could attract several categories of investors.

Private equity funds

Private equity firms with experience in healthcare services could view Indira IVF as a platform for further expansion.

The company’s national footprint, specialised services and potential for acquisitions could fit the investment strategies of funds seeking exposure to India’s healthcare market.

Global healthcare investors

International healthcare investors may be interested in India’s fertility treatment sector because it offers a combination of specialised medical services and a large addressable population.

A large clinic network could also provide opportunities for investment in research, technology, laboratory infrastructure and clinical capabilities.

Strategic healthcare companies

Established hospital groups and healthcare service providers could potentially explore the acquisition as a way to expand their presence in reproductive medicine.

However, a strategic buyer would need to evaluate how fertility clinics fit within its existing operations and whether the acquisition offers meaningful operating or geographic synergies.

No prospective buyer has been publicly confirmed in the reported sale discussions.

Competition is increasing in India’s fertility services market

Indira IVF operates in a market where organised competitors are also expanding.

Nova IVF Fertility is among the major fertility clinic networks in India. Other specialist providers and independent clinics compete for patients across different regions.

Competition increasingly involves more than the number of clinics.

Providers must build strong medical teams, maintain laboratory quality, invest in technology and establish trust with patients.

The sector also faces operational challenges because fertility treatments can involve multiple appointments, diagnostic procedures and treatment cycles.

Patient experience, clinical transparency and consistent treatment standards are important to the long-term reputation of a fertility provider.

For Indira IVF, maintaining its position while expanding through acquisitions will require continued investment in clinical infrastructure and quality management.

Risks a potential buyer will examine

Despite the growth opportunity, a potential acquisition of Indira IVF would involve several risks.

Clinical quality: Fertility treatment outcomes can vary depending on patient circumstances, age, medical history and treatment protocols. Maintaining consistent standards across a large network is essential.

Doctor and specialist retention: The business depends on experienced fertility specialists, embryologists and medical professionals. Retaining key talent could be important during a change of ownership.

Regulatory compliance: Fertility services are subject to healthcare regulations, including India’s Assisted Reproductive Technology (Regulation) Act, 2021, and associated rules.

Reputation and patient trust: Fertility treatment is sensitive and personal. Complaints, poor patient experiences or concerns about clinical practices can affect brand reputation.

Acquisition integration: Expanding through acquisitions can create operational complexity, especially when integrating different clinical teams, laboratories and management systems.

Valuation risk: A high acquisition price could reduce investment returns if future earnings growth does not meet expectations.

These factors will likely form part of the due diligence process if EQT proceeds with a formal sale.

The bigger picture

The reported sale discussions reflect the growing role of private equity in India’s specialised healthcare market.

Fertility services have attracted investors because the sector combines specialised medical expertise, expanding patient awareness and relatively low treatment penetration compared with developed markets.

Indira IVF has built a large national network over several decades and attracted institutional investment from TA Associates and EQT.

A potential transaction at a valuation of at least $1.5 billion would provide an important test of how private investors value India’s organised fertility services businesses.

The outcome could also influence valuations and investment strategies across other healthcare segments, including diagnostics, speciality hospitals and reproductive medicine.

However, the reported valuation remains preliminary, and a sale is not guaranteed.

Looking ahead

The next stage will depend on whether EQT moves from preliminary discussions to a formal sale process and whether prospective buyers are willing to meet its valuation expectations. The company’s financial performance, clinic-level profitability, acquisition strategy and regulatory compliance will be central to any buyer’s assessment. If a transaction proceeds, it could become one of the notable private equity exits in India’s healthcare services sector.

For EQT, a sale would offer an alternative to the IPO route previously explored for Indira IVF. For the Indian fertility market, the process could provide a new reference point for valuing large specialist healthcare networks. Until a buyer, transaction structure and final price are disclosed, the reported $1.5 billion figure should be viewed as an indicative valuation sought by the seller rather than a confirmed deal value.

Get the day’s top stories in your inbox

One concise email. No spam, unsubscribe anytime.